SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-024153
Filing Date
2020-05-11
Accepted
2020-05-11 16:02:10
Documents
86
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q srne-10q_20200331.htm   iXBRL 10-Q 2218066
2 EX-10.2 srne-ex102_166.htm EX-10.2 63711
3 EX-10.3 srne-ex103_167.htm EX-10.3 48008
4 EX-31.1 srne-ex311_10.htm EX-31.1 17154
5 EX-31.2 srne-ex312_9.htm EX-31.2 16764
6 EX-32.1 srne-ex321_8.htm EX-32.1 14922
  Complete submission text file 0001564590-20-024153.txt   9801162

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA srne-20200331.xsd EX-101.SCH 80067
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE srne-20200331_cal.xml EX-101.CAL 73902
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE srne-20200331_def.xml EX-101.DEF 317661
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE srne-20200331_lab.xml EX-101.LAB 580744
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE srne-20200331_pre.xml EX-101.PRE 472693
12 EXTRACTED XBRL INSTANCE DOCUMENT srne-10q_20200331_htm.xml XML 1864766
Mailing Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121
Business Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121 858-203-4100
Sorrento Therapeutics, Inc. (Filer) CIK: 0000850261 (see all company filings)

IRS No.: 330344842 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36150 | Film No.: 20864672
SIC: 2836 Biological Products, (No Diagnostic Substances)